Medical devices, healthcare technology and the business of care
510(k) clearance · K253301

BraiN20 (BraiN20)

Time IS Brain, S.L. · Decision date Jun 27, 2026

FDA DECISIONK253301

What did the FDA decide?

FDA records K253301 as a 510(k) premarket notification, with a decision dated Jun 27, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Neurology
Decision date
Jun 27, 2026

FDA source record

Regulatory record facts

Identifier
K253301
Regulatory pathway
510(k) premarket notification
Product code
GWF
Decision code
SESE
Decision date
Jun 27, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, Electrical, Evoked Response.

Product code
GWF
FDA device class
2

FDA decision timeline

  1. K253301 received

    Application receipt date recorded by FDA.

  2. K253301 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code GWF

Product / regulatory recordCompanyPathwayDecision dateSource
inomed Medizintechnik GmbH510(k) clearanceSep 24, 2026FDA
Alphatec Spine, Inc.510(k) clearanceJan 11, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Time IS Brain, S.L.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Badalona

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records